Tulane University School of Medicine
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Tulane University School of Medicine sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).
Tulane University School of Medicine: 16 sponsored US clinical trials, 1 recruiting.
Tulane University School of Medicine sponsors 16 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 13 completed. 4 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypertension, with 2 trials.
Top-decile sponsor footprint
Tulane University School of Medicine ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
16 total, page 1 of 1
Tulane iPredict, Prevent Study to Evaluate the Progression of Atrial Myopathy.
NCT04703166
Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence
NCT04704050
Use of Death Cafes to Prevent Burnout in ICU Healthcare Employees
NCT04347811
Intensive Care Unit (ICU) Diary Project
NCT04305353
Promoting Medication Adherence Among Older Adults With Hypertension
NCT02846220
Efficacy of Delayed Enhancement MRI-Guided Ablation vs Conventional Catheter Ablation of Atrial Fibrillation
NCT02529319
Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes
NCT02796170
Patient Compliance With Long-Acting Reversible Contraception Administration
NCT03305081
To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study
NCT02299388
Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus
NCT02046395
Diabetes Remote Care Management System
NCT01354015
Evaluation of Behavior, Executive Function, Neurotransmitter Function and Genomic Expression Kuvan Nonresponders
NCT01274026
D-cycloserine Adjunctive Treatment for Posttraumatic Stress Disorder (PTSD) in Adolescents
NCT01157429
Effect of D-cycloserine on Treatment of Posttraumatic Stress Disorder (PTSD) in Youth
NCT01157416
Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients
NCT01361035
Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors
NCT00221195
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the Tulane University School of Medicine pipeline
1 recruiting of 16 indexed (6% open); 13 completed (81%).
Phase mix: 4 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: Hypertension (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Tulane University School of Medicine: open-pipeline peers nationwide
Peers matched on 16 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
Tulane University School of Medicine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 16 trials (± recruiting share)
- Accelerated Community Oncology Research Network · 16 trials · 0% recruiting
- Altimmune · 16 trials · 6% recruiting
- American University · 16 trials · 13% recruiting
- Anthera Pharmaceuticals · 16 trials · 0% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Albert Einstein Healthcare Network · 6% recruiting · 48 trials
- Bassett Healthcare · 6% recruiting · 16 trials
- Dynavax Technologies Corporation · 6% recruiting · 16 trials
- East Tennessee State University · 6% recruiting · 16 trials
Related
What to do with this Tulane University School of Medicine page
16 registered trials is a research-attention snapshot, not an endorsement of Tulane University School of Medicine or any single study.
- 1 of Tulane University School of Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hypertension is the condition Tulane University School of Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypertension trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Tulane University School of Medicine pipeline card: 16 registered trials from official public datasets.Report a data error.